The proposed research definition of Alzheimer’s is defined by the presence of biomarkers — a buildup of plaques and tangles in the brain — which are identified by imaging scans of the brain and samples of cerebrospinal fluid. This change allows researchers to better design clinical trials, include the right participants and learn more about the disease in its earlier stages.
Here’s why it’s important: The classic symptoms of Alzheimer’s disease don’t define or diagnose it. They’re a complication of the changes in the brain that do define the disease — and these brain changes can occur long before the symptoms show up. This change in research may lead to earlier diagnosis of Alzheimer’s disease, which will hopefully lead to delayed progression and better treatments.